Citations (65)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Frank J Senatore, Jonathan Wilmot & John W Birk. (2016) Helicobacter pylori treatment: Still a work in progress. Postgraduate Medicine 128:1, pages 152-157.
Read now
Read now
W. A. de Boer, E. A. M. Joosen. (1999) Disease Management in Ulcer Disease. Scandinavian Journal of Gastroenterology 34:230, pages 23-28.
Read now
Read now
Articles from other publishers (63)
Nicolás Zuluaga Arbelaez, Elsy Cristina Sierra-Vargas, Luis Gonzalo Guevara-Casallas & Santiago Pérez-Viana. (2021) Estrategias terapéuticas para Helicobacter pylori en Colombia. CES Medicina 35:3, pages 244-256.
Crossref
Crossref
Olga P. NyssenAngeles Perez-AisaBojan TepesManuel Castro-FernandezJuozas KupcinskasLaimas JonaitisLuis BujandaAlfredo LucendoNatasa Brglez JurecicJorge Perez-LasalaOleg ShvetsGalina FadeenkoJose M. HuguetZdenki KikecDmitry BordinIrina VoynovanMarcis LejaJose Carlos MachadoMiguel AreiaLuis Fernandez-SalazarLuis RodrigoSergey AlekseenkoJesus BarrioJuan OrtuñoMonica PeronaLiudmila VologzhaninaPilar Mata RomeroOleg ZaytsevTheodore RokkasSotirios GeorgopoulosRinaldo PellicanoGyorgy M. BuzasInes ModolellBlas Jose Gomez RodriguezIlkay SimsekCem SimsekMarina Roldan LafuenteTatiana IlchishinaJudith Gomez CamareroManuel Dominguez-CajalVassiliki NtouliNatalia Nikolaevna DekhnichPerminder PhullOscar NuñezFrode LerangMarino VeneritoFrederic HeluwaertAnte TonkicMaria CaldasIgnasi PuigFrancis MegraudColm O'MorainJavier P. Gisbert. (2021) Adverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg). American Journal of Gastroenterology 116:6, pages 1220-1229.
Crossref
Crossref
Sami AÇAR. (2020) Helikobakter Pylori Eradikasyonunda Modifiye Hibrit Tedavi Etkinliği. Zeynep Kamil Tıp Bülteni 51:3, pages 146-150.
Crossref
Crossref
Satoshi Kobayashi, Satoru Joshita, Chikara Yamamoto, Takumi Yanagisawa, Takayuki Miyazawa, Megumi Miyazawa, Daisuke Kubota, Junichi Sato, Takeji Umemura & Eiji Tanaka. (2019) Efficacy and safety of eradication therapy for elderly patients with helicobacter pylori infection. Medicine 98:30, pages e16619.
Crossref
Crossref
Yingjie Ji & Hong Lu. (2018) Meta-analysis: High-dose vs. low-dose metronidazole-containing therapies for Helicobacter pylori eradication treatment. PLOS ONE 13:1, pages e0189888.
Crossref
Crossref
Richard J.M. Ingram, Krish Ragunath & John C. Atherton. 2015. Yamada' s Textbook of Gastroenterology. Yamada' s Textbook of Gastroenterology
1032
1077
.
G. Sgourakis, A. Pindireki, A. Kouloura, G. Sourtse, V. Ganis, S. Peristeraki, K. Karkoulias, S. Georgopoulos, Ch. Karaliotas & S. Lanitis. (2015) Eradication rates for Helicobacter pylori infection a systematic evidence - based review. Hellenic Journal of Surgery 87:5, pages 377-386.
Crossref
Crossref
Vinayak Nagaraja. (2014)
Evidence-based assessment of proton-pump inhibitors in
Helicobacter pylori
eradication: A systematic review
. World Journal of Gastroenterology 20:40, pages 14527.
Crossref
Crossref
Hyun Jin Song, Jin-Won Kwon, Nayoung Kim & Young Soo Park. (2013) Cost Effectiveness Associated with Helicobacter pylori Screening and Eradication in Patients Taking Nonsteroidal Anti-Inflammatory Drugs and/or Aspirin. Gut and Liver 7:2, pages 182-189.
Crossref
Crossref
C.-H. Kuo, P.-I. Hsu, F.-C. Kuo, S. S. W. Wang, H.-M. Hu, C.-J. Liu, S.-K. Chuah, Y.-H. Chen, M.-C. Hsieh, D.-C. Wu & H.-H. Tseng. (2012) Comparison of 10 day bismuth quadruple therapy with high-dose metronidazole or levofloxacin for second-line Helicobacter pylori therapy: a randomized controlled trial. Journal of Antimicrobial Chemotherapy 68:1, pages 222-228.
Crossref
Crossref
Toshifumi Ohkusa, Kimitoshi Kato, Shuichi Terao, Toshimi Chiba, Katsuhiro Mabe, Kazunari Murakami, Yuji Mizokami, Toshiro Sugiyama, Akinori Yanaka, Yoshiaki Takeuchi, Shigeru Yamato, Tetsuji Yokoyama, Isao Okayasu, Sumio Watanabe, Hisao Tajiri & Nobuhiro Sato. (2010) Newly Developed Antibiotic Combination Therapy for Ulcerative Colitis: A Double-Blind Placebo-Controlled Multicenter Trial. American Journal of Gastroenterology 105:8, pages 1820-1829.
Crossref
Crossref
Qinjuan Sun, Xiao Liang, Qing Zheng, Wenzhong Liu, Shudong Xiao, Weiqi Gu & Hong Lu. (2010)
High Efficacy of 14‐Day Triple Therapy‐Based, Bismuth‐Containing Quadruple Therapy for Initial
Helicobacter pylori
Eradication
. Helicobacter 15:3, pages 233-238.
Crossref
Crossref
Toshiki Uehara, Kimitoshi Kato, Toshifumi Ohkusa, Masahiko Sugitani, Yukimoto Ishii, Norimichi Nemoto & Mitsuhiko Moriyama. (2010) Efficacy of antibiotic combination therapy in patients with active ulcerative colitis, including refractory or steroid-dependent cases. Journal of Gastroenterology and Hepatology 25, pages S62-S66.
Crossref
Crossref
Soon Beom KwonKook Lae LeeJoon Suk KimJae Kyung LeeWon KimYong Jin JungJi Bong JeongJi Won KimByeong Gwan Kim. (2010)
Antibiotics-associated Diarrhea and Other Gastrointestinal Abnormal Responses Regarding
Helicobacter pylori
Eradication
. The Korean Journal of Gastroenterology 56:4, pages 229.
Crossref
Crossref
Seyed Mohsen Dehghani, Asma Erjaee, Mohammad Hadi Imanieh & Mahmood Haghighat. (2008) Efficacy of the Standard Quadruple Therapy Versus Triple Therapies Containing Proton Pump Inhibitor Plus Amoxicillin and Clarithromycin or Amoxicillin-Clavulanic Acid and Metronidazole for Helicobacter pylori Eradication in Children. Digestive Diseases and Sciences 54:8, pages 1720-1724.
Crossref
Crossref
David Y Graham & Akiko Shiotani. (2008) New concepts of resistance in the treatment of Helicobacter pylori infections. Nature Clinical Practice Gastroenterology & Hepatology 5:6, pages 321-331.
Crossref
Crossref
David Y Graham, Hong Lu & Yoshio Yamaoka. (2008) Therapy for Helicobacter pylori Infection Can be Improved. Drugs 68:6, pages 725-736.
Crossref
Crossref
György M Buzás & Jolán Józan. (2007) Nitrofuran-based regimens for the eradication of Helicobacter pylori infection. Journal of Gastroenterology and Hepatology 22:10, pages 1571-1581.
Crossref
Crossref
Hidekazu Suzuki, Toshifumi Hibi & Barry James Marshall. (2007) Helicobacter pylori: present status and future prospects in Japan. Journal of Gastroenterology 42:1, pages 1-15.
Crossref
Crossref
Ratha-Korn Vilaichone, Varocha Mahachai & David Y. Graham. (2006) Helicobacter pylori Diagnosis and Management. Gastroenterology Clinics of North America 35:2, pages 229-247.
Crossref
Crossref
Seyed Amir Mirbagheri, Mehrdad Hasibi, Mehdi Abouzari & Armin Rashidi. (2006)
Triple, standard quadruple and ampicillin-sulbactam-based quadruple therapies for
H pylori
eradication: A comparative three-armed randomized clinical trial
. World Journal of Gastroenterology 12:30, pages 4888.
Crossref
Crossref
Brennan M. R. Spiegel, Chiun-Fang Chiou & Joshua J. Ofman. (2005) Minimizing complications from nonsteroidal antiinflammatory drugs: Cost-effectiveness of competing strategies in varying risk groups. Arthritis & Rheumatism 53:2, pages 185-197.
Crossref
Crossref
N L A Arents, J C Thijs & J H Kleibeuker. (2002) A rational approach to uninvestigated dyspepsia in primary care: review of the literature. Postgraduate Medical Journal 78:926, pages 707-716.
Crossref
Crossref
Brennan M.R. Spiegel, Nimish B. Vakil & Joshua J. Ofman. (2002) Dyspepsia management in primary care: A decision analysis of competing strategies. Gastroenterology 122:5, pages 1270-1285.
Crossref
Crossref
C. Ecclissato, M.A.M. Marchioretto, S. Mendonça, A.P.O. Godoy, R.A. Guersoni, M. Deguer, H. Piovesan, J.G.P. Ferraz & J. PedrazzoliJrJr. (2002)
Increased Primary Resistance to Recommended Antibiotics Negatively Affects
Helicobacter pylori
Eradication
. Helicobacter 7:1, pages 53-59.
Crossref
Crossref
M. Dehesa, J. Larisch, M. Dibildox, M. Di Silvio, L.H. Lopez, E. Ramirez-Barba & J. Torres. (2002) Comparison of Three 7-Day Pantoprazole-Based Helicobacter pylori Eradication Regimens in a Mexican Population with High Metronidazole Resistance. Clinical Drug Investigation 22:2, pages 75-85.
Crossref
Crossref
Mehmet Ungan, Hakan Kulaçoǧlu & Burçak Kayhan. (2001) Cure rates obtained with five different Helicobacter pylori eradication protocols in patients with duodenal ulcer: a prospective, open-label randomized study in a primary care setting in Turkey. Current Therapeutic Research 62:6, pages 462-472.
Crossref
Crossref
A. Armuzzi, F. Cremonini, F. Bartolozzi, F. Canducci, M. Candelli, V. Ojetti, G. Cammarota, M. Anti, A. De Lorenzo, P. Pola, G. Gasbarrini & A. Gasbarrini. (2008)
The effect of oral administration of
Lactobacillus GG
on antibiotic‐associated gastrointestinal side‐effects during
Helicobacter pylori
eradication therapy
. Alimentary Pharmacology & Therapeutics 15:2, pages 163-169.
Crossref
Crossref
Dong H. Kwon, Miae Lee, J. J. Kim, J. G. Kim, F. A. K. El-Zaatari, M. S. Osato & D. Y. Graham. (2001)
Furazolidone- and Nitrofurantoin-Resistant
Helicobacter pylori
: Prevalence and Role of Genes Involved in Metronidazole Resistance
. Antimicrobial Agents and Chemotherapy 45:1, pages 306-308.
Crossref
Crossref
Michael S Osato, Rita Reddy, Siddartha G Reddy, Rebecca L Penland & David Y Graham. (2001) Comparison of the Etest and the NCCLS-approved agar dilution method to detect metronidazole and clarithromycin resistant Helicobacter pylori. International Journal of Antimicrobial Agents 17:1, pages 39-44.
Crossref
Crossref
Savarino, Zentilin, Pivari, Bisso, M. Raffaella Mele, Bilardi, Borro, Dulbecco, Tessieri, Mansi, Borgonovo, De Salvo & Vigneri. (2001)
The impact of antibiotic resistance on the efficacy of three 7‐day regimens against
Helicobacter pylori
. Alimentary Pharmacology & Therapeutics 14:7, pages 893-900.
Crossref
Crossref
Kathleen A Fairman & Brenda R Motheral. (2016)
Helicobacter Pylori
Eradication in Clinical Practice: Retreatment Rates and Costs of Competing Regimens
. Annals of Pharmacotherapy 34:6, pages 721-728.
Crossref
Crossref
Wink A. Boer, Ruud J.X.M. Etten, Peter M. Schneeberger & Guido N.J. Tytgat. (2000) A single drug for Helicobacter pylori infection: first results with a new bismuth triple monocapsule. The American Journal of Gastroenterology 95:3, pages 641-645.
Crossref
Crossref
Xavier Calvet, Llùcia Titó, Ricard Comet, Neus García, Ralel CampoEnric Brullet. (2001)
Four‐Day, Twice Daily, Quadruple Therapy with Amoxicillin, Clarithromycin, Tinidazole and Omeprazole to Cure
Helicobacter pylori
Infection: A Pilot Study
. Helicobacter 5:1, pages 52-56.
Crossref
Crossref
Ferenc Pakodi, Omar M.E Abdel-Salam, Andras Debreceni & Gyula Mózsik. (2000) Helicobacter pylori. One bacterium and a broad spectrum of human disease! An overview. Journal of Physiology-Paris 94:2, pages 139-152.
Crossref
Crossref
T. J. Borody. 2000. Helicobacter pylori. Helicobacter pylori
623
629
.
W. A. De Boer. 2000. Helicobacter pylori. Helicobacter pylori
609
621
.
Yuqiang Nie, Yuyuan Li, Huisheng Wu, Weihong Sha, Hong Du, Shoujun Dai, Hong Wang & Qinglin Li. (2002)
Colloidal Bismuth Pectin: An Alternative to Bismuth Subcitrate for the Treatment of
Helicobacter pylori
– Positive Duodenal Ulcer
. Helicobacter 4:2, pages 128-134.
Crossref
Crossref
X. Calvet, M. -T. López-Lorente, M.-J Cubells, M Barè, E. Gálvez & E. Molina. (1999)
Two-week dual vs. one-week triple therapy for cure of
Helicobacter pylori
infection in primary care: a multicentre, randomized trial
. Alimentary Pharmacology & Therapeutics 13:6, pages 781-786.
Crossref
Crossref
LIU, XIAO, SHI, WU, ZHANG, XU & TYTGAT. (1999) Furazolidone-containing short-term triple therapies are effective in the treatment of Helicobacter pylori infection. Alimentary Pharmacology & Therapeutics 13:3, pages 317-322.
Crossref
Crossref
XIAO, LIU, HU, XIA & TYTGAT. (1999) High cure rate of Helicobacter pylori infection using tripotassium dicitrato bismuthate, furazolidone and clarithromycin triple therapy for 1 week. Alimentary Pharmacology & Therapeutics 13:3, pages 311-315.
Crossref
Crossref
Seiichi KatoHideyo RitsunoKenji OhnumaKazuie IinumaToshiro Sugiyama & Masahiro Asaka. (2006)
Safety and Efficacy of One‐Week Triple Therapy for Eradicating
Helicobacter pylori
in Children
. Helicobacter 3:4, pages 278-282.
Crossref
Crossref
Philip E. Coudron & Charles W. Stratton. (1998) The bactericidal activity of clarithromycin versus ampicillin alone and in combination with omeprazole and/or bismuth against clarithromycin-susceptible and clarithromycin-resistant strains of Helicobacter pylori. Diagnostic Microbiology and Infectious Disease 32:1, pages 39-44.
Crossref
Crossref
X Calvet, N García, R Campo, E Brullet, R Comet & M Navarro. (1998) Two-Day Quadruple Therapy for Cure of Helicobacter pylori Infection: A Comparative, Randomized Trial. American Journal of Gastroenterology 93:6, pages 932-934.
Crossref
Crossref
F. Gomollón, J.A. Ducóns, L. Gimeno, J. Fuentes, S. García, J. Vera & M. Montoro. (2001) The Ideal Therapy Must Be Def ined in Each Geographical Area: Experience with a Quadruple Therapy in Spain. Helicobacter 3:2, pages 110-114.
Crossref
Crossref
Talley, Full-Young, Wyatt, Adams, Lau, Borody, Tseng-Shing, Daskolopolos, Cheung & Talley. (1998)
Nizatidine in combination with amoxycillin and clarithromycin in the treatment of
Helicobacter pylori
infection
. Alimentary Pharmacology & Therapeutics 12:6, pages 527-532.
Crossref
Crossref
Ohkusa, Takashimizu, Fujiki, Araki, Ariake, Shimoi, Honda, Enomoto, Sakurazawa, Horiuchi, Suzuki, Ishii & Ishikura. (1998) Prospective evaluation of a new anti-ulcer agent, ecabet sodium, for the treatment of Helicobacter pylori infection. Alimentary Pharmacology & Therapeutics 12:5, pages 457-461.
Crossref
Crossref
Leonardo Marzio, Domenico Angelucci, Laurino Grossi, Maria Grazia Diodoro, Emanuela Di Campli & Luigina Cellini. (1998) Anti- Helicobacter pylori Specific Antibody Immunohistochemistry Improves the Diagnostic Accuracy of Helicobacter pylori in Biopsy Specimen From Patients Treated With Triple Therapy. American Journal of Gastroenterology 93:2, pages 223-226.
Crossref
Crossref
F Lerang, B Mourn, E Ragnhildstveit, P K Sandvei, P Tolås, J E Whist, M Henriksen, J B Haug & T Berge. (1998) Simplified 10-Day Bismuth Triple Therapy for Cure of Helicobacter pylori Infection: Experience From Clinical Practice in a Population With a High Frequency of Metronidazole Resistance. American Journal of Gastroenterology 93:2, pages 212-216.
Crossref
Crossref
W. A. De Boer, R. J. X. M. Van Etten, Coremans & Schneeberger. (2001)
Two‐day ‘weekend’ lansoprazole‐quadruple therapy for
Helicobacter pylori
infection
. Alimentary Pharmacology & Therapeutics 12:1, pages 77-81.
Crossref
Crossref
Natalie Sohn. (1998) Dyspepsia and ulcers. Primary Care Update for OB/GYNS 5:1, pages 24-27.
Crossref
Crossref
W. A. De Boer. 1998. Helicobacter pylori. Helicobacter pylori
456
461
.
Humphrey J. O’connorJoseph LoaneHolger BindelAbdul S. BhuttaKevin Cunnane. (2008)
One Week Triple Therapy for
Helicobacter pylori:
Does High‐dose Clarithromycin Confer Additional Benef it?
. Helicobacter 2:4, pages 199-204.
Crossref
Crossref
Charles W. Stratton & Philip E. Coudron. (1997) A practical approach to the diagnosis and therapy of helicobacter pylori infection. Antimicrobics and Infectious Diseases Newsletter 16:11, pages 81-86.
Crossref
Crossref
V. Savarino, C. Mansi, M. R. Mele, G. Bisso, G. S. Mela, A. Saggioro, M. Caroli, S. Vigneri, R. Termini, A. Olivieri, R Tosatto & G. Celle. (1997) A new 1-week therapy for Helicobacter pylori eradication: rani- tidine bismuth citrate plus two antibiotics. Alimentary Pharmacology and Therapeutics 11:4, pages 699-703.
Crossref
Crossref
W. A. DE BOER, R. J. X. M. VAN ETTEN, R. W. B. SCHADE, M. E. OUWEHAND, P. M. SCHNEEBERGER, A. J. M. VAN UNNIK & G. N. J. TYTGAT. (1997) One-day intensified lansoprazole-quadruple therapy for cure of Helicobacter pylori infection. Alimentary Pharmacology and Therapeutics 11:1, pages 109-112.
Crossref
Crossref
C Stewart Goodwin, Michael M Mendall & Timothy C Northfield. (1997) Helicobacter pylori infection. The Lancet 349:9047, pages 265-269.
Crossref
Crossref
A. A. Zwet, W. A. Boer, P. M. Schneeberger, J. Weel, A. R. Jansz & J. C. Thijs. (1996) Prevalence of primaryHelicobacter pylori resistance to metronidazole and clarithromycin in The Netherlands. European Journal of Clinical Microbiology & Infectious Diseases 15:11, pages 861-864.
Crossref
Crossref
Wink A. de Boer, Ruud J. X. M. van Etten, J. Y. L. Lai, Peter M. Schneeberger, Branka A. M. van De Wouw & Willem M. M. Driessen. (2007) Effectiveness of Quadruple Therapy Using Lansoprazole, Instead of Omeprazole, in Curing Helicobacter pylori Infection. Helicobacter 1:3, pages 145-150.
Crossref
Crossref
W. A. de Boer. (1996) How to Achieve a Near 100% Cure Rate for H. Pylori Infection in Peptic Ulcer Patients. Journal of Clinical Gastroenterology 22:4, pages 313-316.
Crossref
Crossref
BILLY BOURKE, NICOLA JONES & PHILIP SHERMAN. (1996) Helicobacter pylori infection and peptic ulcer disease in children. The Pediatric Infectious Disease Journal 15:1, pages 1-13.
Crossref
Crossref
W. A. DE BOER, W. M. M. DRIESSEN & G. N. J. TYTGAT. (2007)
Only four days of quadruple therapy can effectively cure Helicobacter pylori
infection
. Alimentary Pharmacology & Therapeutics 9:6, pages 633-638.
Crossref
Crossref
G.D. Bell, K.U. Powell, Vincenzo Savarino, Giuseppe Sandro Mela, Sergio Vigneri, Guido Celle, G. Treiber, O. Klotz, F. Gomollón, E. Bajador, Wink de Boer, Sint Anna Ziekenhuis & Guido Tytgat. (1995) Helicobacter pylori eradication and reinfection. The Lancet 345:8965, pages 1646-1648.
Crossref
Crossref